- Home
- PINS vs MRNA Comparison
PINS vs MRNA Comparison
Compare PINS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINS
- MRNA
- Stock Information
- Founded
- PINS 2008
- MRNA 2010
- Country
- PINS United States
- MRNA United States
- Employees
- PINS N/A
- MRNA N/A
- Industry
- PINS Computer Software: Programming Data Processing
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PINS Technology
- MRNA Health Care
- Exchange
- PINS Nasdaq
- MRNA Nasdaq
- Market Cap
- PINS 19.9B
- MRNA 10.6B
- IPO Year
- PINS 2019
- MRNA 2018
- Fundamental
- Price
- PINS $27.88
- MRNA $24.38
- Analyst Decision
- PINS Buy
- MRNA Hold
- Analyst Count
- PINS 29
- MRNA 20
- Target Price
- PINS $40.44
- MRNA $51.94
- AVG Volume (30 Days)
- PINS 11.6M
- MRNA 8.6M
- Earning Date
- PINS 05-08-2025
- MRNA 05-01-2025
- Dividend Yield
- PINS N/A
- MRNA N/A
- EPS Growth
- PINS N/A
- MRNA N/A
- EPS
- PINS 2.67
- MRNA N/A
- Revenue
- PINS $3,646,166,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- PINS $16.31
- MRNA N/A
- Revenue Next Year
- PINS $15.94
- MRNA $22.14
- P/E Ratio
- PINS $10.44
- MRNA N/A
- Revenue Growth
- PINS 19.35
- MRNA N/A
- 52 Week Low
- PINS $23.68
- MRNA $23.15
- 52 Week High
- PINS $45.19
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- PINS 52.90
- MRNA 38.42
- Support Level
- PINS $24.43
- MRNA $23.70
- Resistance Level
- PINS $27.63
- MRNA $28.52
- Average True Range (ATR)
- PINS 1.03
- MRNA 1.43
- MACD
- PINS 0.52
- MRNA -0.04
- Stochastic Oscillator
- PINS 88.77
- MRNA 20.19
About PINS Pinterest Inc.
Pinterest is a social media platform with a focus on product and idea discovery. Pinterest users, or pinners, can leverage the platform as they go about gathering ideas on topics such as home improvement, fashion, cooking, and travel. The company has more than 500 million monthly active users, two thirds of whom are female. Pinterest generates revenue by selling digital ads on its platform. While the platform's user base spans the globe, the vast majority of its revenue stems from ads shown to North American users.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.